- Home
- LDP vs PHAR Comparison
LDP vs PHAR Comparison
Compare LDP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDP | PHAR |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LDP | PHAR |
|---|---|---|
| Price | $21.27 | $16.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | ★ 102.5K | 23.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $362,274,000.00 |
| Revenue This Year | N/A | $24.80 |
| Revenue Next Year | N/A | $6.84 |
| P/E Ratio | ★ N/A | $2,921.20 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $16.16 | $7.50 |
| 52 Week High | $20.30 | $18.12 |
Technical Indicators
Market Signals| Indicator | LDP | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 50.29 |
| Support Level | $21.16 | $16.23 |
| Resistance Level | $21.35 | $17.00 |
| Average True Range (ATR) | 0.17 | 0.74 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 28.20 | 31.99 |
Price Performance
Historical ComparisonAbout LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.